Compare iShares MSCI Hong Kong ETF (EWH) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Organon & Co. Common Stock — how do they compare? iShares MSCI Hong Kong ETF trades at $21.92 (market cap $1.21B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Organon & Co. Common Stock is far larger — about 3× iShares MSCI Hong Kong ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 63 Days and Organon & Co. Common Stock for 0 Days on average.
| EWH | OGN | |
|---|---|---|
Market Cap | $1.21B | $3.61B |
Volume | 9,334,618 | 1,808,049 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $13.81 |
52-Week Low | $20.92 | $5.70 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | — | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.35 with a 1.78% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster tightly around $22.
The outlook remains cautious given Hong Kong's market volatility and geopolitical risks. Investment opportunity exists for contrarian bets on Chinese tech recovery, but risks include sustained Fed tightening and regional tensions. Wall Street sentiment is divided, with some seeing value in oversold conditions while others warn of further downside.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
